LONDON (ShareCast) - (Sharecast News) - Life sciences business OptiBiotix Health provided revenue guidance for its recently wrapped up trading year on Friday and told investors it was now eyeing up a dual-listing on the New York Stock Exchange as it forecast profitability in 2020.
Optibiotix said total sales for the 12 months ended 30 November came to £808,000. When including the £617,000 received from the disposal of a small tranche of shares in its sister company SkinBioTherapeutics, total income came to £1.43m - up from the £541,614 recorded a year earlier.

The AIM-listed group added that in 2020, numbers should get a boost from the launch of its SlimBiome weight management range in healthcare chain Holland and Barrett and a roll-out in Italy of Ezimega 3, which contains Opibiotix's cholesterol-lowering additive.

Optibiotix said: "Whilst there are no guarantees these will all deliver expected sales revenues, our focus is on developing each division (Prebiotic, Probiotic, and Consumer Health) to reach profitability in 2020."

The firm also noted it toying with the idea of a Nasdaq floating, as high investor and consumer interest in its microbiome in the USA and growing sales led the board to commission advisors to explore the potential of a dual listing.

As of 1100 GMT, Optibiotix shares were down 8.91% at 50.10p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE